-
公开(公告)号：US10800738B2
公开(公告)日：2020-10-13
申请号：US16749744
申请日：2020-01-22
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： John R. Snoonian , Harold Scott Wilkinson , Haitao Zhang
IPC: C07D207/09
Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.
-
公开(公告)号：US10576058B2
公开(公告)日：2020-03-03
申请号：US16452880
申请日：2019-06-26
Applicant: Sunovion Pharmaceuticals Inc.
Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
-
公开(公告)号：US12161623B2
公开(公告)日：2024-12-10
申请号：US17977920
申请日：2022-10-31
Applicant: Sunovion Pharmaceuticals Inc.
Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
-
公开(公告)号：US11136304B2
公开(公告)日：2021-10-05
申请号：US16817749
申请日：2020-03-13
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Nandkumar Nivritti Bhogle , Takahiko Hashizuka , Robert Joseph Prytko , John R. Snoonian , Harold Scott Wilkinson , Haitao Zhang
IPC: C07D311/76
Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
-
公开(公告)号：US20210061759A1
公开(公告)日：2021-03-04
申请号：US16994835
申请日：2020-08-17
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： John R. Snoonian , Harold Scott Wilkinson , Haitao Zhang
IPC: C07D207/09
Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.
-
Patent Agency Ranking
公开(公告)号：US10660875B1
公开(公告)日：2020-05-26
申请号：US16738261
申请日：2020-01-09
Applicant: Sunovion Pharmaceuticals Inc.
Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
-
公开(公告)号：US20190167635A1
公开(公告)日：2019-06-06
申请号：US16209412
申请日：2018-12-04
Applicant: Sunovion Pharmaceuticals Inc.
Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
-
公开(公告)号：US20180215702A1
公开(公告)日：2018-08-02
申请号：US15882498
申请日：2018-01-29
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Charles Vandenbossche , John R. Snoonian
IPC: C07C231/10 , C07C249/08 , C07C231/12 , C07C209/62 , C07C233/91
CPC classification number: C07C231/10 , C07B2200/07 , C07C209/50 , C07C209/62 , C07C231/12 , C07C233/91 , C07C249/08 , C07C2601/14 , C07C2602/10 , C07C233/05 , C07C251/44 , C07C251/38 , C07C211/56
Abstract: A convenient method for converting oximes into enamides is disclosed. The process produces enamides without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines.
-
公开(公告)号：US11767293B2
公开(公告)日：2023-09-26
申请号：US17748165
申请日：2022-05-19
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： John R. Snoonian , Harold Scott Wilkinson , Haitao Zhang
IPC: C07D207/09
CPC classification number: C07D207/09 , C07B2200/13
Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.
-
公开(公告)号：US11517558B2
公开(公告)日：2022-12-06
申请号：US17097799
申请日：2020-11-13
Applicant: Sunovion Pharmaceuticals Inc.
Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.02 seconds)
